Experimental Helicobacter pylori infection in humans: a multifaceted challenge
- Preventive and Therapeutic Vaccines Against Helicobacter Pylori: Current Status and Future Challenges. Ernst, Peter B.; Pappo, Jacques // Current Pharmaceutical Design;Oct2000, Vol. 6 Issue 15, p1557
Approximately 50% of humanity is infected with Helicobacter pylori. Normally, this is a life-long infection indicating that the host response to natural infection fails to yield protective immunity. Moreover, the chronic inflammatory response associated with this infection can contribute to...
- Helicobacter pylori serostatus ini Peruvian families: The case for sibling-to-sibling transmission. Passaro, D.J.; Sisirak, J.; Maguina, P.; Gilman, R. // Gut;Sep2002 Supplement 2, Vol. 51, pA31
Background: Most H. pylori (Hp) infection begins in childhood, but the transmission dynamics of acute infection are not well understood. To investigate the familial determinants of pediatric Hp infection, we conducted a cross-sectional serostudy among families living in a shantytown near Lima,...
- Role of host additive factors in the immune response to H. pylori infection. Queiroz, D.M.M.; Rocha, G.A.; Rocha, A.M.C.; Silva, L.D.; Gazzinelli, A.; Corrêa-Oliveira, R.; Bethony, J. // Gut;Sep2002 Supplement 2, Vol. 51, pA34
Our previous study pointed to the importance of intrafamiliar transmission of Helicobacter pylori infection. However, an aspect overlooked was the overlap between shared residence and kinship. Therefore, we evaluated the influence of demographic, environmental and host additive genetic factors...
- First isolation of Helicobacter pylori from plaque of dental caries patients in Western Nigeria. Oyedeji, K.S.; Smith, S.I.; Opere, B.O.; Adefihan, L. // Gut;Sep2002 Supplement 2, Vol. 51, pA37
Background and Aim: The mode of transmission of Helicobacter pylori is still a subject of debate. Some workers have suggested faeco-oral, oraloral, water-borne etc.,. Since the most probable justification for oral-oral transmission is the isolation of the organism from oral cavity; this is a...
- New vaccines. // MLO: Medical Laboratory Observer;Dec2009, Vol. 41 Issue 12, p9
The article reports on the plans of Eurocine Vaccines to develop a nasal vaccine against Helicobacter pylori in collabration with the research company Helicure.
- Ulcer vaccine. Rodgers, Katie // Drug Topics;9/18/95, Vol. 139 Issue 18, p38
Reports that OraVax is developing an oral vaccine against H. pylori, the infectious organism responsible for the development of peptic ulcers. Results of animal studies; Composition of the oral vaccine.
- Similar efficacy seen in three treatments for H. pylori. // Infectious Disease News;Jun2013, Vol. 26 Issue 6, p18
The article discusses the results of a study which showed similar efficacy among triple therapy, sequential therapy and concomitant therapy in eliminating Helicobacter pylori infection, presented at the Digestive Disease Week conference held in Orlando, Florida from May 18-21, 2013.
- Track B2: Infectious disease and risk groups. // European Journal of Public Health;Feb2006 Supplement 1, Vol. 16, p30
The article presents abstracts of research on infectious diseases and risk groups in Europe. They include "Prevalence of isolated anti-hepatitis B core in risk groups participating in the hepatitis B vaccination campaign in the Netherlands," "HIV testing among military conscripts in Finland...
- Cost-Effectiveness of a Potential Prophylactic Helicobacter pylori Vaccine in the United States. Rupnow, Marcia F. T.; Chang, Alicia H.; Shachter, Ross D.; Owens, Douglas K.; Parsonnet, Julie // Journal of Infectious Diseases;10/15/2009, Vol. 200 Issue 8, p1311
Background. Helicobacter pylori vaccines are under development to prevent infection. We quantified the cost effectiveness of such a vaccine in the United States, using a dynamic transmission model. Methods. We compartmentalized the population by age, infection status, and clinical disease state...